Compound and composition for modulating uric acid levels

Abstract

The present invention relates to a compound of formula (II), or ester or tautomer thereof: wherein: W is O, S, S(O), S(O)2, NH, N(optionally substituted alkyl), CH2, CH2O, CH2S or CH2NH; Ri is H, F, Cl, Br, I, CH2F, CRzH, CF3, CN, OH, NO2, NH(alkyl) or N(alkyl)(alkyl), SO2CH3, SO2NH2, SO2NHCH3, CO2-alkyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkoxy, optionally substituted S-alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted aryl or optionally substituted heteroaryl; a is 0,1 or 2; Ra is H or optionally substituted C1-3 alkyl; Ra’ isΉ or optionally substituted Ct^ alkyl; or Ra and Ra* together with the carbon atom to which they are attached form an optionally substituted, 3-, 4-, 5- or 6-membered ring, optionally comprising 1 or 2 heteroatoms selected from Ο, N and S; Rb, Rc, Re arid Rf are each independently H, F, Cl, Br, I, CF3, CN, alkyl, cycloalkyl, cydopropylmethyl, NH2, NHR', NR’R", OH, OR', SH, SR', C(O)R', CO2H, COOR', CONH2, CONHR', CONR'R", SO3H, S(O)2R’, S(O)2NH2, S(O)2NHR', S(O)2NR'Rb, aryl, heterocyclyl or heteroaryl; Rd is F, Cl, Br. I, CF3.CN, NH2t NHR', NR^, OH, OR*, SH, SR’, C(O)R', CO2H, COOR', CONH2, CONHR', CONR’R", SO3H, S(O)2R', S(O)2NH2, S(O)2NHR', S(O)2NR'R", aryl, heterocyclyl or heteroaryl; wherein R' is methyl,, pthyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, cyclopropyl, cyclobutyl, cyclpftentyl, cyclohexyl, cydopropylmethyl or phenyl; R" is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyi, cyclopropyl, cyclobutyt, cyclopentyl, cydohexyl, cydopropylmethyl or phenyl; or R' and R" together with the nitrogen atom to which they are attached form an optionally substituted, saturated or unsaturated 4-, 5- or 6-membered heterocyclic ring; or Rb and Rc, or Rc and Rd, or Rd and R®, or Re and Rf together with the two carbon atoms to which they are attached, form an optionally substituted, aromatic or non-aromatic, 5-, 6ογ'7-membered ring, optionally comprising 1 or 2 heteroatoms selected from Ο, N and, S, and wherein said ring may be pptfonally fused to 1 or 2 additional optionally substituted, aromatic or non-aromatic, 5-, 6- or 7-membered rings, optionally comprising 1 or 2 heteroatoms selected from Ο, N and S; and wherein the optional substituents are each independently F, Cl, Br, I, CF3, CN, alkyl, cycldalkyl, cydopropylmethyl, NH2, NHR', NR'R", OH, OR', SH, SR’,C(O)R', CO2H, COOR', CONH2, CONHR*, CONR'R'', SOsH, S(O)2R’, S(O)2NH2, S(O)2NHR', S(O)2NR'R", aryl, heterocyclyl or heteroaryl; x is 0 or 1; y is 0 or 1; z is 0' or 1; Rx, Rx‘, Ry, Ry,R2 and Rz' are each independently H,F,C|,Br, or optionally substituted C1-3 alkyl; or Rx and Rx', or Ry and Ry1, or R2 and R2', or Rx and Ry, or Ry and R2, or Rx and R2 together with the carbon atoms to which they are attached, form an optionally substituted, aromatic or non-aromatic, 3-7 membered ring, optionally comprising 1 or 2 heteroatoms selected from Ο, N and* S, and wherein said ring may be optionally fused to 1 or 2 additional optionally substituted, aromatic or non-aromatic, 5-, 6- or 7-membered rings, optionally comprising 1 or 2 heteroatoms selected from O, Nand S; A is H, C(O)O-B1 or C(O)NH-B2; wherein B1 is H, optionally substituted C1-6 alkyl or a pharmaceutically acceptable cation; B2 is H or optionally substituted Ci-e alkyl; and wherein all alkyl, alkylene, cycloalkyl, heterocyclyl, aryl and heteroaryl moieties may be optionally further substituted; and pharmaceutical composition comprising a therapeutically effective amount of.the cornpound for use ip the treatment pf gput and hypOruri^rriia.